Reduces MYC expressionReduced breast cancer cell viability via induction of ULP17Combined treatment-induced cell death, tumor regression and clamped PI3K signaling in various cancer cell linesSignificantly attenuates the expression of c-MYC, BCL2 and CDK4/6, while synergistically inducing apoptosis of cultured and primary CD34+ human AML blast progenitor cellsSensitizes colon, breast and ovarian cancer cells to JQ1 and dBET1; combination of these two types of inhibitors increased apoptosis and downregulated MYC. Here, BCL2 is linked to breast cancer.